EWTX News and Press, Edgewise Therapeutics Inc. From 01/04/23

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41 st Annual...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...

– Webcast event to feature preclinical data of its lead hypertrophic cardiomyopathy (HCM) candidate and commentary by a renowned cardiologist – – Management to provide 2023 Company outlook at the 41 st Annual J.P. Morgan Healthcare Conference on January 10, 2023...

– Former Chief Medical Officer of MyoKardia and Renovacor to lead cardiovascular development at Edgewise – Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies...

Edgewise Therapeutics press release ( NASDAQ: EWTX ): Q3 GAAP EPS of -$0.34 beats by $0.02 . Cash, cash equivalents and marketable securities were $365 million as of September 30, 2022. For further details see: Edgewise Therapeutics GAAP EPS of -$0.34 beats b...

– Announced positive 6-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD) – – Advancing CANYON Phase 2 trial in BMD and initiated LYNX Phase 2 trial in Duchenne muscular dystrophy (DMD) – ...

Edgewise Therapeutics ( NASDAQ: EWTX ) on Thursday said it had started a phase 2 trial of its molecule EDG-5506 for the treatment of Duchenne muscular dystrophy (DMD). Shares of the clinical-stage biopharma earlier closed -5.8% at $9.34. The mid-stage trial, c...

– Rare Disease Research, LLC first site activated to enroll children with DMD – – Edgewise to hold virtual webinars with the patient community to discuss EDG-5506 clinical trials in November – Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinica...

– Continued positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history trajectories – – Highly significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarker...